Daniel Greenblatt
Neurodevelopmental Disabilities · Latham, NYNPI 1962638965
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $688 and has fallen 76.6% since, to $161 in 2023.
Across 115 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$409
- Tris Pharma Inc$392
- Neurelis, Inc.$381
- Supernus Pharmaceuticals, Inc.$279
- Eisai Inc.$142
- UCB, Inc.$131
- plus $545 from 13 others
What the payments were for
- Food & beverage$2,278100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 20 | $409 |
| Tris Pharma Inc | 12 | $392 |
| Neurelis, Inc. | 15 | $381 |
| Supernus Pharmaceuticals, Inc. | 22 | $279 |
| Eisai Inc. | 7 | $142 |
| UCB, Inc. | 5 | $131 |
| Livanova USA, Inc. | 6 | $106 |
| Sunovion Pharmaceuticals Inc. | 7 | $99 |
| Corium, LLC | 5 | $90 |
| Vertical Pharmaceuticals, LLC | 4 | $55 |
| Biogen | 2 | $38 |
| AstraZeneca(2 entities) | 2 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Greenwich Biosciences, Inc. | 2 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $19 |
| Zogenix Inc. | 1 | $16 |
| Biomarin Pharmaceutical Inc. | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dyanavel XR$145
- VALTOCO$117
How this compares
Too few neurodevelopmental disabilities providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Other neurodevelopmental disabilities in Latham
- Deepa RastogiBronx$11K
- Chuan ChangNew York$2K
- David KaufmanNew York$506
- Ivan PavkovicNew Hyde Park$328
- Cristina Fernandez CarbonellNew Hyde Park$150
- Jennifer NguyenRochester$142
- Michael EliceWoodbury$129
- Gerardo TolentinoPort Jefferson Station$128
- Suanne MallenbaumLarchmont$53
- Paola CarugnoBronx$17
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.